In an open-label, randomized, phase 2 trial (NCT03329690), therapy with trastuzumab led to significant improvements in response and OS, compared with standard chemotherapy, among patients with HER2-positive GC (median, 12.5 vs. 8.4 months; hazard ratio for death, 0.59; 95% confidence interval, 0.39 to 0.88; P=0.01) (6). Here, ERBB2 is linked to gastric cancer.